Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
19.23
-0.48 (-2.44%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 | 2018 - 2014 |
Revenue | 19.65 | 240.74 | 243.23 | 138.29 | 87.99 | 168.8 | Upgrade
|
Revenue Growth (YoY) | -92.33% | -1.03% | 75.89% | 57.16% | -47.87% | 945.67% | Upgrade
|
Gross Profit | 19.65 | 240.74 | 243.23 | 138.29 | 87.99 | 168.8 | Upgrade
|
Selling, General & Admin | 121.22 | 108.82 | 137.38 | 85.44 | 54 | 26.56 | Upgrade
|
Research & Development | 445.64 | 336.92 | 284.36 | 201.88 | 127.15 | 81.05 | Upgrade
|
Operating Expenses | 566.86 | 445.74 | 421.74 | 287.32 | 181.15 | 107.61 | Upgrade
|
Operating Income | -547.21 | -205 | -178.51 | -149.04 | -93.16 | 61.19 | Upgrade
|
Interest Expense | -22.97 | -18.33 | - | - | - | - | Upgrade
|
Interest & Investment Income | 19.44 | 15.3 | 5.03 | 6.12 | 9.19 | 6.96 | Upgrade
|
Other Non Operating Income (Expenses) | 2.09 | 1.54 | 0.77 | 2.07 | -0.6 | - | Upgrade
|
EBT Excluding Unusual Items | -548.65 | -206.49 | -172.71 | -140.85 | -84.57 | 68.15 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | - | 0.02 | - | Upgrade
|
Pretax Income | -548.65 | -206.49 | -172.71 | -140.85 | -84.55 | 68.15 | Upgrade
|
Income Tax Expense | -1.29 | 2.78 | 3.79 | 0 | 0 | 0.17 | Upgrade
|
Earnings From Continuing Operations | -547.36 | -209.28 | -176.49 | -140.85 | -84.55 | 67.98 | Upgrade
|
Net Income to Company | -547.36 | -209.28 | -176.49 | -140.85 | -84.55 | 67.98 | Upgrade
|
Minority Interest in Earnings | 8.73 | 4 | 0.43 | - | - | - | Upgrade
|
Net Income | -538.64 | -205.28 | -176.06 | -140.85 | -84.55 | 67.98 | Upgrade
|
Net Income to Common | -538.64 | -205.28 | -176.06 | -140.85 | -84.55 | 67.98 | Upgrade
|
Shares Outstanding (Basic) | 115 | 107 | 105 | 104 | 101 | 94 | Upgrade
|
Shares Outstanding (Diluted) | 115 | 107 | 105 | 104 | 101 | 99 | Upgrade
|
Shares Change (YoY) | 8.53% | 1.26% | 1.62% | 3.00% | 2.14% | 17.90% | Upgrade
|
EPS (Basic) | -4.66 | -1.92 | -1.67 | -1.36 | -0.84 | 0.72 | Upgrade
|
EPS (Diluted) | -4.66 | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 | Upgrade
|
Free Cash Flow | -532.65 | -330.63 | -188.91 | 147.75 | -107.75 | 161.03 | Upgrade
|
Free Cash Flow Per Share | -4.61 | -3.10 | -1.79 | 1.42 | -1.07 | 1.63 | Upgrade
|
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
Operating Margin | -2785.05% | -85.16% | -73.39% | -107.77% | -105.87% | 36.25% | Upgrade
|
Profit Margin | -2741.43% | -85.27% | -72.39% | -101.85% | -96.09% | 40.27% | Upgrade
|
Free Cash Flow Margin | -2710.95% | -137.34% | -77.67% | 106.84% | -122.46% | 95.40% | Upgrade
|
EBITDA | -529.78 | -192.51 | -168.09 | -140.77 | -87.22 | 65.63 | Upgrade
|
EBITDA Margin | - | -79.97% | -69.11% | -101.79% | -99.12% | 38.88% | Upgrade
|
D&A For EBITDA | 17.43 | 12.49 | 10.42 | 8.27 | 5.94 | 4.44 | Upgrade
|
EBIT | -547.21 | -205 | -178.51 | -149.04 | -93.16 | 61.19 | Upgrade
|
EBIT Margin | - | -85.16% | -73.39% | -107.77% | -105.87% | 36.25% | Upgrade
|
Effective Tax Rate | - | - | - | - | - | 0.26% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.